抗TIGIT抗体は、がん免疫療法において有望なアプローチとして登場し、さまざまな種類のがん、特に固形がんの患者に新たな希望を提供しています。TIGIT (T cell immunoreceptor with Ig and ITIM domains) は、T細胞およびナチュラルキラー (NK) 細胞に発現する阻害性受容体で、免疫応答の調節に重要な役割を果たしています。TIGITを標的とすることで、研究者は免疫系ががん細胞を認識して排除する能力を強化し、がん治療戦略に革命をもたらす可能性を秘めています。
目次
Table of Content
1. Introduction to Anti TIGIT Antibody
1.1 Overview
1.2 Mechanism of Anti TIGIT Antibodies
1.3 Clinical Approaches to Target TIGIT
2. Global Anti TIGIT Antibodies Clinical Trials Overview
2.1 By Company
2.2 By Country
2.3 By Indication
2.4 By Patient Segment
2.5 By Phase
3. Global Anti TIGIT Antibodies Clinical Pipeline By Company, Indication and Phase
3.1 Research
3.2 Preclinical
3.3 Phase I
3.4 Phase I/II
3.5 Phase II
3.6 Phase III
4. Global Anti TIGIT Antibodies Market Outlook
4.1 Current Clinical and Market Trends
4.2 Future Market Outlook
5. Anti TIGIT Antibodies Market Trends by Indication
5.1 Cancer
5.2 Autoimmune and Inflammatory Disorders
5.3 Microbial Infections
6. Anti TIGIT Antibodies Market By Country
6.1 US
6.2 China
6.3 South Korea
6.4 Australia
6.5 UK
7. Combinations Approaches for TIGIT Therapy
8. TIGIT Co Inhibition with PD1 or PDL1
9. Global Anti TIGIT Antibodies Market Dynamics
9.1 Market Drivers
9.2 Commercialization Challenges
10. Competitive Landscape
10.1 Akeso Biopharma
10.2 BeiGene
10.3 Bio-Thera Solutions
10.4 Biotheus
10.5 Compugen
10.6 FutureGen Biopharmaceutical
10.7 Merck Sharp and Dohme
10.8 Nanjing Sanhome Pharmaceutical
10.9 OriCell Therapeutics
10.10 Phio Pharmaceuticals
10.11 Roche
10.12 Shanghai Henlius Biotech
10.13 Shanghai Junshi Biosciences
10.14 Simcere Pharmaceutical Group
10.15 Tasrif Pharmaceutical
List of Figures & Tables
Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
Figure 1-2: TIGIT Inhibitor - Proposed Mechanism of Action
Figure 1*3: TIGIT Inhibitor - Mechanism of Action
Figure 1-4: Binding Efficacy of Monoclonal Antibody
Figure 1-5: Binding Efficacy of Bispecific Antibodies
Figure 1-6: Advantages of Small Molecule Drugs over Therapeutic Antibodies
Figure 2-1: Global - Anti TIGIT Antibodies Clinical Trials by Company (Number of Drugs), 2024 -2028
Figure 2-2: Global - Anti TIGIT Antibodies Clinical Trials by Country (Number of Drugs), 2024 - 2028
Figure 2-3: Global - Anti TIGIT Antibodies Clinical Trials by Indication (Number of Drugs), 2024 - 2028
Figure 2-4: Global - Anti TIGIT Antibodies Clinical Trials by Patient Segment (Number of Drugs), 2024 - 2028
Figure 2-5: Global - Anti TIGIT Antibodies Clinical Trials by Phase (Number of Drugs), 2024 -2028
Figure 4 1: Global TIGIT Therapy Fundamental Companies
Figure 4 2: Future TIGIT Market
Figure 5-1: Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207) Phase I/II (NCT04150965) Study - Initiation and Completion Year
Figure 5-2: Compugen TIGIT Antibody Cancer Pipeline
Figure 5-3: Keio University School of Medicine Research Study
Figure 5-4: University of Zurich Investigation for TIGIT Antibody to Cure Viral Infection
Figure 5-5: Combination TIGIT Therapy for Viral Infections
Figure 6-1: PD-1 Inhibitor Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) Phase II (NCT05130177) Study - Initiation and Completion Year
Figure 6-2: iTeos Therapeutics and GSK Triumph Enrolment Milestone
Figure 6-3: Bristol Myers Squibb and Agenus Preclinical Candidates, BMS-986442
Figure 6-4: Clinical TIGIT Therapy Pipeline in China
Figure 6-5: JS006 Monotherapy and in Combination With Toripalimab Phase I (NCT05061628) Study - Initiation and Completion Year
Figure 6-6: Chinese Companies TIGIT Candidates Insights
Figure 6-7: Zimberelimab with Domvanalimab Phase II (NCT04262856) Study - Initiation and Completion Year
Figure 6-8: Aspects Influencing South Korea TIGIT Market
Figure 6-9: HLX301 Phase I/II (NCT05102214) Study - Initiation and Completion Year
Figure 6-10: AZD8205 Monotherapy or in Combination with Anticancer Drugs Phase I/II (NCT05123482) Study - Initiation and Completion Year
Figure 6-11: Key Players in UK TIGIT Market
Figure 7-1: TIGIT Therapy Combinations
Figure 9-1: Global - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 9-2: TIGIT Inhibitor Market Drivers
Figure 9-3: Stages of Drug Development
Table 1-1: Anti-TIGIT Monoclonal Antibodies in Development
Table 5-1: Ongoing Cancers Clinical Trials for TIGIT Therapy
Table 6-1: Ongoing US Clinical Trials for TIGIT Therapy
Table 6-2: Ongoing China Clinical Trials for TIGIT Therapy
Table 7-1: Ongoing Preclinical and Clinical Trials for Combination of TIGIT inhibitors
